Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
AUE | Ann: AUE NTA 03-10-2024 $2.99044 | 07:35 | 0 | 22 | |||
|
|||||||
AUE | Ann: AUE NTA 02-10-2024 $2.98138 | 03/10/24 | 0 | 34 | |||
|
|||||||
AUE | Ann: AUE NTA 01-10-2024 $2.97748 | 02/10/24 | 0 | 28 | |||
|
|||||||
AUE | Ann: AUE NTA 30-09-2024 $2.99372 | 01/10/24 | 0 | 36 | |||
|
|||||||
AUE | Ann: AUE NTA 27-09-2024 $2.98369 | 30/09/24 | 0 | 42 | |||
|
|||||||
AUE | Ann: AUE NTA 26-09-2024 $2.97363 | 27/09/24 | 0 | 39 | |||
|
|||||||
AUE | Ann: AUE NTA 25-09-2024 $2.93416 | 26/09/24 | 0 | 29 | |||
|
|||||||
AUE | Ann: AUE NTA 24-09-2024 $2.95878 | 25/09/24 | 0 | 49 | |||
|
See All Discussions